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Volume 55, Number 3 Abstracts 887medical care plus supervised exercise therapy. A change in peak walking time
on a graded treadmill test at 6 months was the primary end point. Secondary
end points included assessment of quality of life with the Walking Impair-
ment Questionnaire, the Peripheral Artery Questionnaire, and the Medical
Outcomes Study 12-Item Short Form as well as free-living step activities. At
6 months of follow-up, changes in peak walking time (the primary end
point) were greatest for supervised exercise, intermediate for stent revascu-
larization, and most poor with optimal medical management alone, with a
mean change vs baseline of 5.8  4.6, 3.7  4.9, and 1.2  2.6 minutes,
respectively (P  .001 comparing supervised exercise vs optimal medical
treatment; P  .02 comparing stent therapy vs optimal medical treatment,
and P .04 comparing supervised exercise vs stent therapy). Disease-specific
quality of life assessed by the Walking Impairment Questionnaire and the
Peripheral Artery Questionnaire improved with supervised exercise and stent
therapy compared with optimal medical treatment alone. In general, the
extent of improvement was greater with stent therapy than with supervised
exercise. Free-living step activity increased more with stents than with
supervised exercise or optimal medical treatment alone, but differences were
not statistically significant.
Comment: CLEVER was a well-conducted clinical trial. It was, how-
ever, hampered by low enrollment, a common problem with comparative
effectiveness trials. It remains difficult to know what to do with the data.
Walking on a treadmill is perhaps not all that relevant to real life. In addition,
the primary end point was measured at the time patients completed super-
vised exercise, and whether the effects of supervised exercise will hold up in
the long-term is unknown. One wonders if the better improvement of
patient-perceived quality of life with stent therapy reflects the placebo effect
of having undergone an intervention or does the improved performance on
the treadmill with exercise therapy reflect a treadmill training effect?
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Conclusion: Carotid duplex ultrasound surveillance programs are
costly and inefficient.
Summary: The Asymptomatic Carotid Surgery (ACS) trial and the
Asymptomatic Carotid Atherosclerosis Study (ACST) study indicate benefit
for the combination of carotid endarterectomy (CEA) and best medical
management vs best medical management alone in patients with high-grade
asymptomatic carotid stenosis. That benefit, however, is relatively small and
now under considerable question given current availability and penetrance
q
sf the use of better antiplatelet agents and statin medications to prevent
eurologic events in patients with asymptomatic carotid stenosis. Given
hat may be a declining benefit of prophylactic carotid intervention, con-
roversy has arisen about the effectiveness of carotid duplex surveillance
rograms. Timing of surveillance, justifications for surveillance, and poten-
ial cost-effectiveness must be justified by clear documentation of rates of
rogression of carotid stenosis, rates of development of postintervention
estenosis, and clinical consequences of progression of stenosis in native
rteries, post-CEA arteries, or those that have been stented. The authors
herefore evaluated the effectiveness of their surveillance program for pa-
ients with asymptomatic carotid stenosis 50% or who had undergone
arotid intervention. Points evaluated included whether their surveillance
rogram resulted in changes in clinical management, prevented stroke, and
he cost of the surveillance program per stroke prevented. They reviewed a
-year vascular surgical database to identify patients enrolled in their carotid
uplex ultrasound surveillance program for asymptomatic carotid stenosis or
fter CEA. The time of the review was January 1, 2000, through December
1, 2008. The authors also noted the number of duplex scans and CEAs
erformed in the patients through March 2010. They used the results of
CAS to estimate the number of strokes prevented by CEA in their study
opulation. They then used reimbursement data to assess the average cost of
ach duplex ultrasound study performed and the cost for each stroke
revented by their duplex ultrasound surveillance program. During the
eriod under observation, 11,531 carotid duplex scans were performed on
,003 patients (mean, 3.84 scans per patient). CEA for asymptomatic
arotid stenosis was performed on 225 patients (7.5%). The duplex surveil-
ance program, by the authors’ calculations, prevented approximately 13
trokes (871 carotid duplex scans/stroke prevented). The mean cost of each
uplex scan was $332.00  $170.00. The total cost of the duplex ultra-
ound surveillance program was therefore $3,830,000, an equivalent of
290,000 per stroke prevented.
Comment: The perceived effectiveness and cost-effectiveness of ca-
otid duplex ultrasound surveillance programs should be questioned. The
tudy raises a significant question: Do carotid duplex surveillance programs
rimarily benefit physicians, vascular laboratories, or patients? The fact that
40% of the patients had only two duplex ultrasound scans performed
uring the surveillance period is a serious study limitation. Follow-up was,
owever, comparable to other studies in the literature and therefore the
esults likely can be generally applied to other practices. The personal and
conomic impact of stroke is huge, but this report still calls into serious
uestion the use of limited health care resources to fund carotid duplex
urveillance programs.
